Ignite Creation Date:
2025-12-24 @ 3:28 PM
Ignite Modification Date:
2025-12-26 @ 6:10 AM
Study NCT ID:
NCT00225992
Status:
TERMINATED
Last Update Posted:
2012-10-11
First Post:
2005-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
Sponsor:
Oncology Specialties, Alabama
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-02
Start Date Type:
None
Primary Completion Date:
2007-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-11
Completion Date Type:
ACTUAL
First Submit Date:
2005-09-22
First Submit QC Date:
None
Study First Post Date:
2005-09-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-10-10
Last Update Post Date:
2012-10-11
Last Update Post Date Type:
ESTIMATED